Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients
Y Wang, Z Tong, W Zhang, W Zhang, A Buzdin… - Frontiers in …, 2021 - frontiersin.org
A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …
A Marabelle, M Fakih, J Lopez, M Shah… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of …
response to immune checkpoint blockade. We prospectively explored the association of …
[HTML][HTML] Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms …
DM Merino, LM McShane, D Fabrizio… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Tumor mutational burden (TMB), defined as the number of somatic mutations
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C …
S Peters, R Dziadziuszko, A Morabito, E Felip… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
[HTML][HTML] Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Background High tumor mutation burden (TMB) can benefit immunotherapy for multiple
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …
Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence
SJ Klempner, D Fabrizio, S Bane, M Reinhart… - The …, 2020 - academic.oup.com
Abstract Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a
proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number …
proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number …
[HTML][HTML] Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
R Cristescu, D Aurora-Garg, A Albright… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Several studies have evaluated the relationship between tumor mutational
burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 …
burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 …
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB)≥ 10: a decision centered on empowering patients and their …
On 16 June 2020, the US Food and Drug Administration (FDA) granted accelerated
approval to pembrolizumab for the treatment of 'adult and pediatric patients with …
approval to pembrolizumab for the treatment of 'adult and pediatric patients with …
[HTML][HTML] The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of …
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …
with NSCLC and have led to unprecedented improvements in response rates and survival in …